|
| 35196631 | Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer. | Biochem Biophys Res Commun | 2022 |
| 35092134 | N-glycosylation regulates MET processing and signaling. | Cancer Sci | 2022 |
| 35085554 | SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells. | J Biol Chem | 2022 |
| 34805784 | De novo peptide grafting to a self-assembling nanocapsule yields a hepatocyte growth factor receptor agonist. | iScience | 2021 |
| 33574034 | CDCP1 promotes compensatory renal growth by integrating Src and Met signaling. | Life Sci Alliance | 2021 |
| 35011963 | Placental Leucine Aminopeptidase as a Potential Specific Urine Biomarker for Invasive Ovarian Cancer. | J Clin Med | 2021 |
| 34948276 | Recent Insights into Human Endometrial Peptidases in Blastocyst Implantation via Shedding of Microvesicles. | Int J Mol Sci | 2021 |
| 34502141 | Dimer Interface in Natural Variant NK1 Is Dispensable for HGF-Dependent Met Receptor Activation. | Int J Mol Sci | 2021 |
| 32929081 | Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. | Nat Commun | 2020 |
| 31664167 | Retraction Note: Enhanced suppression of tumor growth using a combination of NK4 plasmid DNA-PEG engrafted cationized dextran complex and ultrasound irradiation. | Cancer Gene Ther | 2020 |
| 31765716 | New insights into human endometrial aminopeptidases in both implantation and menstruation. | Biochim Biophys Acta Proteins Proteom | 2020 |
| 31943091 | The constitutive high-affinity Met-binding site in the kringle domain is dispensable for the signalling activity of hepatocyte growth factor. | J Biochem | 2020 |
| 33028834 | Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion. | Sci Rep | 2020 |
| 33121208 | Cyclic Peptide-Based Biologics Regulating HGF-MET. | Int J Mol Sci | 2020 |
| 31101918 | Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor. | Nat Chem Biol | 2019 |
| 31212972 | Distinct Localization of Mature HGF from its Precursor Form in Developing and Repairing the Stomach. | Int J Mol Sci | 2019 |
| 31342590 | Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer. | Cancer Sci | 2019 |
| 30322054 | MET Activation by a Macrocyclic Peptide Agonist that Couples to Biological Responses Differently from HGF in a Context-Dependent Manner. | Int J Mol Sci | 2018 |
| 30405161 | Cellular signaling and gene expression profiles evoked by a bivalent macrocyclic peptide that serves as an artificial MET receptor agonist. | Sci Rep | 2018 |
| 28064454 | Hepatocyte growth factor/MET in cancer progression and biomarker discovery. | Cancer Sci | 2017 |
| 28294470 | Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. | Cancer Sci | 2017 |
| 28094206 | Hepatocyte growth factor in physiology and infectious diseases. | Cytokine | 2017 |
| 28973887 | Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer. | Proc Natl Acad Sci U S A | 2017 |
| 28673936 | Targeting the hepatocyte growth factor/Met pathway in cancer. | Biochem Soc Trans | 2017 |
| 26719536 | Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. | Cancer Res | 2016 |
| 27608665 | Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies. | Sci Rep | 2016 |
| 27683122 | Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma. | Oncotarget | 2016 |
| 25770121 | Hepatocyte growth factor and Met in drug discovery. | J Biochem | 2015 |
| 26191485 | A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. | Springerplus | 2015 |
| 25758345 | Artificial human Met agonists based on macrocycle scaffolds. | Nat Commun | 2015 |
| 24952482 | Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. | Oncotarget | 2014 |
| 28548072 | HGF-Met Pathway in Regeneration and Drug Discovery. | Biomedicines | 2014 |
| 25378205 | Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury. | Pharmacology | 2014 |
| 24780821 | Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor. | Exp Cell Res | 2014 |
| 24828661 | Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. | J Thorac Oncol | 2014 |
| 23047829 | Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans. | J Pharm Sci | 2013 |
| 24292413 | Novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling. | J Pharmacol Sci | 2013 |
| 24386407 | Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. | PLoS One | 2013 |
| 24118504 | Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. | Cancer Sci | 2013 |
| 24190236 | Suppression of fibrogenic gene expression and liver fibrosis using a synthetic prostacyclin agonist. | Biomed Res | 2013 |
| 23876175 | Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis. | Arthritis Res Ther | 2013 |
| 24033722 | Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. | Cancer Sci | 2013 |
| 23690929 | mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. | PLoS One | 2013 |
| 23676973 | Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. | Circ J | 2013 |
| 23618918 | Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes. | Cytokine | 2013 |
| 23722408 | Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells. | Oncol Rep | 2013 |
| 23507559 | α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. | Cancer Lett | 2013 |
| 23233163 | HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. | Int J Oncol | 2013 |
| 23219794 | Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. | Eur J Pharmacol | 2013 |
| 23319394 | The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. | Int J Cancer | 2013 |